Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Rises By 19.4%

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was the recipient of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 1,979,996 shares, a growth of 19.4% from the February 12th total of 1,658,534 shares. Based on an average daily volume of 340,549 shares, the short-interest ratio is currently 5.8 days. Approximately 5.5% of the company’s shares are short sold. Approximately 5.5% of the company’s shares are short sold. Based on an average daily volume of 340,549 shares, the short-interest ratio is currently 5.8 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on EPRX shares. Cantor Fitzgerald lifted their target price on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen cut Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Friday, January 9th. Finally, Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eupraxia Pharmaceuticals has an average rating of “Buy” and a consensus price target of $15.50.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth about $61,000. TCI Wealth Advisors Inc. bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at about $65,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at approximately $71,000. Bank of America Corp DE raised its position in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares during the period. Finally, Guardian Wealth Advisors LLC NC bought a new position in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $76,000.

Eupraxia Pharmaceuticals Price Performance

Shares of Eupraxia Pharmaceuticals stock traded up $0.03 on Monday, hitting $7.39. 584,420 shares of the company’s stock traded hands, compared to its average volume of 230,442. The firm’s 50-day moving average price is $8.29 and its two-hundred day moving average price is $6.84. The stock has a market capitalization of $265.74 million, a PE ratio of -7.17 and a beta of 1.27. Eupraxia Pharmaceuticals has a one year low of $2.68 and a one year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.21). On average, analysts forecast that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.